What is the 13F Pro Quality Score for DFTX?

13F Pro ranks Definium Therapeutics, Inc. (DFTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DFTX's current score at https://13fpro.ai/research/DFTX (free sign-up required for the full ranking).

Which hedge funds own the most DFTX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DFTX include BlackRock,, DRIEHAUS CAPITAL MANAGEMENT, Avoro Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/DFTX as soon as new 13F filings post.

Where does 13F Pro source DFTX data?

All Definium Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Definium Therapeutics, Inc. files with the SEC under CIK 1813814. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DFTX in?

Definium Therapeutics, Inc. (DFTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DFTX research updated on 13F Pro?

DFTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Definium Therapeutics, Inc.(DFTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1813814 DFTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

DFTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Definium Therapeutics, Inc. (DFTX), a Healthcare sector company. DFTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Definium Therapeutics, Inc. reports net income of $-77.1M, free cash flow of $-42.6M. Top institutional holders of DFTX by reported 13-F value include BlackRock,, DRIEHAUS CAPITAL MANAGEMENT, Avoro Capital Advisors, based on the most recent SEC filings. DFTX trades on the Nasdaq exchange and files with the SEC under CIK 1813814. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DFTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Definium Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-77.1M

Free Cash Flow

Q1 2026

$-42.6M

D/E Ratio

Q1 2026

0.15

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-69.1% YoY

$-183.8MFY 2025

FY22 $-56.8MFY23 $-95.7MFY24 $-108.7MFY25 $-183.8M

Operating Income

-60.0% YoY

$-166.3MFY 2025

FY22 $-66.3MFY23 $-93.9MFY24 $-103.9MFY25 $-166.3M

EPS (Diluted)

-33.8% YoY

$-2.06FY 2025

FY22 $-1.84FY23 $-2.44FY24 $-1.54FY25 $-2.06

Total Assets

+45.7% YoY

$440.1MFY 2025

FY22 $170.0MFY23 $124.5MFY24 $302.2MFY25 $440.1M

Total Debt

+85.7% YoY

$40.6MFY 2025

FY22 —FY23 $14.1MFY24 $21.9MFY25 $40.6M

Op. Cash Flow

-66.3% YoY

$-131.6MFY 2025

FY22 $-50.1MFY23 $-64.4MFY24 $-79.1MFY25 $-131.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-183.8M -69.1%	$-108.7M -13.5%	$-95.7M -68.6%	$-56.8M +39.0%	$-93.0M -174.1%	$-33.9M
Operating Income	$-166.3M -60.0%	$-103.9M -10.7%	$-93.9M -41.5%	$-66.3M +29.3%	$-93.9M -184.1%	$-33.0M
EPS (Diluted)	$-2.06 -33.8%	$-1.54 +36.9%	$-2.44 -32.6%	$-1.84 +45.9%	$-3.40	—
Total Assets	$440.1M +45.7%	$302.2M +142.6%	$124.5M -26.7%	$170.0M +3.7%	$164.0M +101.2%	$81.5M
Total Debt	$40.6M +85.7%	$21.9M +54.7%	$14.1M	—	—	—
Operating Cash Flow	$-131.6M -66.3%	$-79.1M -22.9%	$-64.4M -28.4%	$-50.1M -9.4%	$-45.8M -94.2%	$-23.6M

AI Insight: DFTX Financial Trends

Pre-revenue biotech burning through cash at accelerating pace with quarterly losses reaching $77M in Q1 2026, up from $6M in Q2 2024.

• Net losses accelerated dramatically from $6M in Q2 2024 to $77M in Q1 2026.

• Operating losses widened from $24M in Q2 2024 to $59M in Q1 2026.

• Total debt increased 71% from $24M in Q2 2024 to $41M in Q1 2026.

• Equity dropped to $279M in Q1 2026 from $332M in Q4 2025 despite recent raise.

⚠ Operating cash flow deteriorated to negative $43M in Q1 2026 from negative $20M in Q2 2024.

⚠ Burn rate acceleration suggests heightened funding needs for clinical programs.

AI Insight: DFTX Ratio Trends

Return metrics deteriorated severely with ROE plunging from -11.6% in Q2 2024 to -110.6% in Q1 2026.

• ROE collapsed from -11.6% in Q2 2024 to -110.6% in Q1 2026, showing consistent deterioration.

• ROIC weakened from -43.2% in Q2 2024 to -74.1% in Q1 2026, indicating worsening capital efficiency.

• Debt-to-equity ratio increased from 0.09 in Q4 2024 to 0.15 in Q1 2026.

⚠ D/E spiked to 0.31 in Q3 2025 before moderating to 0.12 in Q4 2025, suggesting financing volatility.

⚠ Operating and net profit margins remain unavailable across all periods, limiting profitability assessment.

Get alerted when DFTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Definium Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DFTX

BlackRock, Inc.
$160.3M8,480,230 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$111.7M5,911,889 sh
Avoro Capital Advisors LLC
$94.5M5,000,000 sh
Deep Track Capital, LP
$56.7M3,000,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$47.2M2,495,399 sh
STATE STREET CORP
$46.7M2,471,873 sh
Octagon Capital Advisors LP
$46.1M2,440,000 sh
Commodore Capital LP
$37.8M2,000,000 sh
FMR LLC
$34.2M1,809,610 sh
Trails Edge Capital Partners, LP
$32.9M1,738,110 sh

Fund	Value	Shares
BlackRock, Inc.	$160.3M	8,480,230
DRIEHAUS CAPITAL MANAGEMENT LLC	$111.7M	5,911,889
Avoro Capital Advisors LLC	$94.5M	5,000,000
Deep Track Capital, LP	$56.7M	3,000,000
GEODE CAPITAL MANAGEMENT, LLC	$47.2M	2,495,399
STATE STREET CORP	$46.7M	2,471,873
Octagon Capital Advisors LP	$46.1M	2,440,000
Commodore Capital LP	$37.8M	2,000,000
FMR LLC	$34.2M	1,809,610
Trails Edge Capital Partners, LP	$32.9M	1,738,110

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DFTX on your watchlist

Track score changes the day Definium Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DFTX a good stock to buy?

13F Pro's AI-powered analysis of Definium Therapeutics, Inc. (DFTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DFTX are available on the DFTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DFTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DFTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Definium Therapeutics, Inc.'s investment landscape.